150708-76-2

Usage

Uses

Used in Pharmaceutical Industry:
BENZYL 2-BENZYL-4-OXO-3,4-DIHYDROPYRIDINE-1(2H)-CARBOXYLATE is used as a precursor or intermediate for the synthesis of other related compounds. Its chemical structure and properties make it a promising candidate for the development of new medications.
Used in Medicinal Chemistry Research:
BENZYL 2-BENZYL-4-OXO-3,4-DIHYDROPYRIDINE-1(2H)-CARBOXYLATE is used as a subject of research for further understanding its properties and potential applications in the field of medicinal chemistry. Its unique structure and functional groups may contribute to the discovery of new therapeutic agents.
Used in Calcium Channel Blocker Development:
As a member of the dihydropyridine class, BENZYL 2-BENZYL-4-OXO-3,4-DIHYDROPYRIDINE-1(2H)-CARBOXYLATE may have potential applications in the development of calcium channel blockers, which are medications used to treat high blood pressure, angina, and certain heart rhythm disorders. Its specific structure could offer new avenues for the treatment of cardiovascular conditions.

Upstream product

• 620-08-6 4-methoxypyridine 
• 100-44-7 benzyl chloride 
• 501-53-1 benzyl chloroformate 
• 6921-34-2 benzylmagnesium chloride 

Downstream Products

• 1003843-26-2 benzyl 2-benzyl-6-ethyl-4-oxopiperidine-1-carboxylate 
• 193201-63-7 (±)-7-(phenylmethyl)-1,4-dioxa-8-azaspiro[4.5]decane 
• 849928-35-4 C₂₀H₂₁NO₃ 
• 150823-15-7 (2R,4R)-2-benzyl-1-t-butyloxycarbonyl-4-hydroxypiperidine 

Relevant academic research and scientific papers

SAR of 2-benzyl-4-aminopiperidines: CGP 49823, an orally and centrally active non-peptide NK1 antagonist

Novel 2-benzyl-4-aminopiperidines have been shown to be potent and selective antagonists at the NK1 receptor. Some compounds of this series, e.g. CGP 49823 (2), show CNS activity after oral administration.

1-acylpiperidine compounds

1-Acylpiperidine compound of the formula I STR1 in which R1 is an optionally substituted aralkyl, aryloxyalkyl, heteroaralkyl, aroyl, heteroaroyl, cycloalkylcarbonyl, aralkanoyl, heteroarylalkanoyl, aralkoxycarbonyl or arylcarbamoyl radical or the acyl radical of an α-amino acid which is optionally N-substituted by lower alkanoyl or carbamoyl-lower-alkanoyl, R2 is cycloalkyl or an optionally substituted aryl or heteroaryl radical, R3 is hydrogen, alkyl, carbamoyl or an alkanoyl or alkenoyl radical which is optionally substituted by carboxyl or esterified or amidated carboxyl, R4 is an optionally substituted aryl or optionally partially hydrogenated heteroaryl radical, X1 is methylene, ethylene, a direct linkage, an optionally ketalised carbonyl group or an optionally etherified hydroxymethylene group, X2 is alkylene, carbonyl or a direct linkage, and X3 is carbonyl, oxo-lower-alkylene, oxo(aza)-lower-alkylene or an alkylene radical which is optionally substituted by phenyl, hydroxymethyl, optionally esterified or amidated carboxyl or, in higher than the α position, by hydroxyl, and its salts have substance-P-antagonistic properties and can be used as pharmaceutically active substances in pharmaceuticals for the treatment of disorders in whose development substance P plays an essential part.